Related Experiment Video

Updated: Jan 27, 2026

Laparoscopic Anterior Right Hepatectomy: A Single-Center Experience
09:51

Laparoscopic Anterior Right Hepatectomy: A Single-Center Experience

Published on: December 4, 2023

1.6K

Clinical outcome in diffuse large B-cell lymphoma with hepatitis C virus infection in the rituximab era: a single

Hiroki Nishikawa1, Mitsuru Tsudo, Yukio Osaki

  • 1Department of Gastroenterology and Hepatology, Osaka Red Cross Hospital, Osaka, Japan. h-nishikawa@osaka-med.jrc.or.jp

Oncology Reports
|June 28, 2012
PubMed

Insights

Hepatitis C virus (HCV) infection did not significantly impact the clinical outcomes or treatment response in diffuse large B-cell lymphoma (DLBCL) patients receiving rituximab-based immunochemotherapy. Hepatotoxicity rates were also similar between infected and non-infected groups.

Area of Science:

  • Oncology
  • Hepatology
  • Immunology

Background:

  • Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma.
  • The role of hepatitis C virus (HCV) infection in DLBCL outcomes during the rituximab era is not fully understood.
  • Rituximab-containing immunochemotherapy has become a standard treatment for DLBCL.

Purpose of the Study:

  • To compare the clinical outcomes, treatment response, and hepatotoxicity in DLBCL patients with and without HCV infection who received rituximab-based immunochemotherapy.
  • To assess the influence of HCV infection on overall survival (OS) and progression-free survival (PFS).
  • To evaluate the incidence and severity of hepatotoxicity in DLBCL patients with and without HCV infection.

Main Methods:

  • Retrospective analysis of 248 DLBCL patients diagnosed between January 2004 and October 2011.
  • Patients were divided into two groups: 28 with HCV infection (HCV group) and 220 without HCV infection (control group).
  • Comparison of OS, PFS, objective response rates, and hepatotoxicity between the two groups.

Main Results:

  • No significant differences in OS (P=0.525) or PFS (P=0.759) were observed between the HCV and control groups.
  • Objective response rates were high in both groups: 92.9% in the HCV group and 95.9% in the control group (P=0.619).
  • Hepatotoxicity occurred in 25.0% of the HCV group and 15.9% of the control group, with no significant difference (P=0.281) and no treatment discontinuation due to hepatotoxicity.

Conclusions:

  • HCV infection does not appear to negatively influence the clinical course of DLBCL patients treated with rituximab-containing immunochemotherapy.
  • Rituximab-based treatment is a safe and effective option for DLBCL patients with HCV infection.
  • Further research may be warranted to explore the long-term impact of HCV in DLBCL management.

More Related Videos

Evaluation of T Follicular Helper Cells and Germinal Center Response During Influenza A Virus Infection in Mice07:07

Evaluation of T Follicular Helper Cells and Germinal Center Response During Influenza A Virus Infection in Mice

Published on: June 27, 2020

5.8K
Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells09:02

Modeling Hepatitis B Virus Infection in Non-Hepatic 293T-NE-3NRs Cells

Published on: June 5, 2020

7.9K

Related Concept Videos

Endocarditis II: Clinical Features of Infective Endocarditis01:25

Endocarditis II: Clinical Features of Infective Endocarditis

Endocarditis can present various clinical features depending on the causative organism and the patient's underlying health conditions. Initially, the clinical features of infective endocarditis develop gradually, presenting with nonspecific symptoms that can be easily mistaken for other illnesses.General SymptomsEarly symptoms of infective endocarditis are fever, chills, weakness, malaise, fatigue, and weight loss. These symptoms reflect the systemic nature of the infection and the body's...
473
Diffusion01:12

Diffusion

Diffusion is the passive movement of substances down their concentration gradients—requiring no expenditure of cellular energy. Substances, such as molecules or ions, diffuse from an area of high concentration to an area of low concentration in the cytosol or across membranes. Eventually, the concentration will even out, with the substance moving randomly but causing no net change in concentration. Such a state is called dynamic equilibrium, which is essential for maintaining overall...
217.3K
Diffusion01:21

Diffusion

Diffusion is a type of passive transport. In passive transport, a substance tends to move from an area of high concentration to an area of low concentration until the concentration is equal across the space. For example, take the diffusion of substances through the air. When someone opens a perfume bottle in a room filled with people, the perfume is at its highest concentration in the bottle and is at its lowest at the edges of the room. The perfume vapor will diffuse, or spread away, from the...
6.3K
What are Viruses?00:50

What are Viruses?

Overview
127.9K
Lattice Centering and Coordination Number02:33

Lattice Centering and Coordination Number

The structure of a crystalline solid, whether a metal or not, is best described by considering its simplest repeating unit, which is referred to as its unit cell. The unit cell consists of lattice points that represent the locations of atoms or ions. The entire structure then consists of this unit cell repeating in three dimensions. The three different types of unit cells present in the cubic lattice are illustrated in Figure 1.
Types of Unit Cells
Imagine taking a large number of identical...
11.5K
Center of Gravity00:58

Center of Gravity

The center of gravity (COG) of an object is the point where the object's total weight is considered to be concentrated. Knowing the location of the center of gravity is useful when predicting the behavior of a moving object or designing static structures. In a uniform gravitational field, the center of gravity is similar to the center of mass (COM); yet, these two points can be positioned differently. For example, the Moon's center of mass lies very close to its geometric center, but...
6.6K